Interchangeable Biosimilars: Key Points for Patients
Defining Interchangeable
Biologics and Their Value
SPEAKER

Jonathan Kay, MD
UMass Memorial Health
Worcester, MA
Part 1
Defining Interchangeable
Biologics and Their ValuePart 2
Achieving Interchangeability
StatusPart 3
Extrapolating Indications
Defining Interchangeable
Biologics and Their ValuePart 2
Achieving Interchangeability
StatusPart 3
Extrapolating Indications
Jonathan Kay, MD, defines biosimilarity and the necessary requirements for that designation and discusses the implications of interchangeability on patient access to biological products.
©2022 Boehringer Ingelheim Inc. All Rights Reserved. SC-US-74798 11/22